Evommune Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
31.0%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$3.38next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Investments Quarterly307MTarget: Sufficient to fund operations through 2028
Quarterly Net Loss Quarterly-217M
Quarterly Research and Development Expenses Quarterly17.3M
Watch Items
- EVO756 Phase 2b top-line data readout in Chronic Spontaneous Urticaria (CSU)Trigger: Primary endpoint of change in Urticaria Activity Score (UAS7) at 12 weeksAction: Evaluate clinical efficacy and safety profile to determine progression to Phase 3 trials
- EVO756 Phase 2b top-line data readout in Atopic Dermatitis (AD)Trigger: Efficacy and safety results in moderate-to-severe AD patientsAction: Assess competitive positioning against existing standard-of-care therapies
- EVO301 Phase 2b trial initiationTrigger: Initiation of dose-ranging trial using a subcutaneous formulationAction: Monitor trial enrollment and clinical site activation
Research as of 19 Jun 2026